Registered outcomes32

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 32

List	Outcome	Time frame	Description
Primary	The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.	Baseline and Week 24.	The increase in High-Density Lipoprotein (HDL) Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
Secondary	Change From Baseline in High-Density Lipoprotein Cholesterol.	Baseline and Week 24.	The change between HDL-Cholesterol collected at week 24 or final visit and HDL-Cholesterol collected at baseline.
Secondary	Change From Baseline in High-Density Lipoprotein/Low-Density Lipoprotein Ratio.	Baseline and Week 24.	The change between High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at week 24 or final visit and High-Density Lipoprotein/Low-Density Lipoprotein Ratio collected at baseline.
Secondary	Change From Baseline in Triglycerides.	Baseline and Week 24.	The change between the value of Triglycerides collected at week 24 or final visit and Triglycerides collected at baseline.
Secondary	Change From Baseline in Low-Density Lipoprotein Subfractions.	Baseline and Week 24.	The change between the value of Low-Density Lipoprotein Subfractions collected at week 24 or final visit and Low-Density Lipoprotein Subfractions collected at baseline.
Secondary	Change From Baseline in Low-Density Lipoprotein Cholesterol.	Baseline and Week 24.	The change between Low-Density Lipoprotein Cholesterol collected at week 24 or final visit and Low-Density Lipoprotein Cholesterol collected at baseline.
Secondary	Change From Baseline in Glycosylated Hemoglobin.	Baseline and Week 24.	The change between the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 or final visit and Glycosylated Hemoglobin collected at baseline.
Secondary	Change From Baseline in Fasting Intact Proinsulin.	Baseline and Week 24.	The change between Fasting Intact Proinsulin collected at week 24 or final visit and Fasting Intact Proinsulin collected at baseline.
Secondary	Change From Baseline in Fasting Glucose.	Baseline and Week 24.	The change between Fasting Glucose collected at week 24 or final visit and Fasting Glucose collected at baseline.
Secondary	Change From Baseline in Adiponectin.	Baseline and Week 24.	The change between Adiponectin collected at week 24 or final visit and Adiponectin collected at baseline.
Secondary	Change From Baseline in High Sensitivity C-reactive Protein (Original).	Baseline and Week 24.	The change between the value of High Sensitivity C-reactive Protein collected at week 24 or final visit and High Sensitivity C-reactive Protein collected at baseline.
Secondary	Change From Baseline in High Sensitivity C-reactive Protein (≤ 10 mg/L).	Baseline and Week 24.	The change between the value of High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at week 24 or final visit and High Sensitivity C-reactive Protein less than or equal to 10 mg/L collected at baseline.
Secondary	Change From Baseline in Systolic Blood Pressure.	Baseline and Week 24.	The change between Systolic Blood Pressure measured at week 24 or final visit and Systolic Blood Pressure measured at baseline.
Secondary	Change From Baseline in Diastolic Blood Pressure.	Baseline and Week 24.	The change between Diastolic Blood Pressure measured at week 24 or final visit and Diastolic Blood Pressure measured at baseline.
Secondary	Intake of Study Medication Greater Than 80% and Less Than 120%.	Baseline and Week 24.	The change between the Intake of study medication greater than 80% at week 24 or final visit and Baseline and the Intake of study medication greater than 80% at baseline.
Secondary	Change From Baseline in Nitrotyrosine.	Baseline and Week 24.	The change between the value of Nitrotyrosine collected at week 24 or final visit and Nitrotyrosine collected at baseline.
Secondary	Change From Baseline in Soluble CD40 Ligand.	Baseline and Week 24.	The change between the value of Soluble CD40 Ligand collected at week 24 or final visit and Soluble CD40 Ligand collected at baseline.
Secondary	Change From Baseline in Matrix Metallo Proteinase-9.	Baseline and Week 24.	The change between the value of Baseline in Matrix Metallo Proteinase-9 collected at week 24 or final visit and Baseline in Matrix Metallo Proteinase-9 collected at baseline.
Secondary	Change From Baseline in Soluble Intracellular Adhesion Molecule.	Baseline and Week 24.	The change between the value of Baseline in Soluble Intracellular Adhesion molecule at week 24 or final visit and Baseline in Soluble Intracellular Adhesion molecule collected at baseline.
Secondary	Change From Baseline in Soluble Vascular Cell Adhesion Molecule.	Baseline and Week 24.	The change between the value of Soluble Vascular Cell Adhesion Molecule collected at week 24 or final visit and Soluble Vascular Cell Adhesion Molecule collected at baseline.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00770653/registered

API reference For AI assistants

Registered outcomes32

Sources 3

Read this list from software.